Professor

enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development

Retrieved on: 
Tuesday, April 9, 2024
NMIBC, BCG, American Urological Association, Master, Professor, Advisory Council, Patient, SVP, Thesis, University, Drug, Society, American College, LEGEND, Bladder cancer, Hofstra University, FACS, Stanford University, AUA, Prostate, Medicine, Pharmaceutical industry

In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.

Key Points: 
  • In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.
  • He joins enGene from Johnson & Johnson Innovative Medicine, where he was most recently the Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer).
  • "We are thrilled to welcome Dr. Raj Pruthi to the enGene team.
  • In addition to his position at enGene, Dr. Pruthi maintains multiple prominent leadership roles within the urological community.

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

GIST Researchers Find the Link Between Human Activity and Shifting Weather Patterns in Western North America

Retrieved on: 
Friday, April 5, 2024
Atmosphere, Gas, Climate change, Earth science, Biophysical environment, Professor, Climate, Atmospheric science, NAO, Doctor of Philosophy, Greenhouse, Dominoes, Weather, Agriculture

GWANGJU, South Korea, April 5, 2024 /PRNewswire/ -- Western North America seems to be experiencing more extreme weather events more frequently.

Key Points: 
  • GWANGJU, South Korea, April 5, 2024 /PRNewswire/ -- Western North America seems to be experiencing more extreme weather events more frequently.
  • The atmosphere is like a network of interconnected pathways that determine how weather systems move and interact across the globe.
  • In the Northern Hemisphere, there are three such major teleconnection patterns that affect winter conditions: the Pacific North American pattern (PNA), the North Atlantic Oscillation (NAO), and the North American winter dipole (NAWD).
  • This, in turn, affects the weather patterns that influence winter conditions in western North America and contribute to recent more frequent extreme weather events.

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Retrieved on: 
Thursday, March 21, 2024
Cancer, Principal, Enzyme, DNA repair, Biochemistry, Survival, Professor, Monroe Dunaway Anderson, Patient, Neoplasm, DNA, History, Breast, Prostate, Protein, University, MD Anderson Cancer Center, PARP, Therapy, ALC1, Chromatin, CSO, LP, Pharmaceutical industry

EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.

Key Points: 
  • EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.
  • By hindering DNA repair, PARP inhibitors cause tumor cell death, and they have been effective therapies for many ovarian, breast, prostate, and pancreatic cancers.
  • EIS-12656 inhibits the chromatin remodeling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation.
  • EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process.

Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology

Retrieved on: 
Wednesday, March 20, 2024
IOP, Ocular hypertension, Professor, NCX, Patient, American Journal, American Journal of Ophthalmology, Glaucoma, Vision science, Intraocular pressure, Pharmaceutical industry

Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025

Key Points: 
  • Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025
    Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.
  • “The data from the Mont Blanc Phase 3 trial demonstrated the potential of NCX 470 and we look forward to seeing confirmation of this clinical profile in the upcoming results from the ongoing Denali Phase 3 trial, expected in H2 2025.
  • The Mont Blanc publication concludes that “The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with open-angle glaucoma or ocular hypertension at all 6 time points.
  • With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.”

Corti Set to Disrupt the Health Wearable Market with the First Real-time, Continuous Monitor for Cortisol and Melatonin Hormones, the Key Stress and Sleep Hormones

Retrieved on: 
Thursday, April 4, 2024
Wearables, Mobile Technology, Technology, Mental Health, Fitness & Nutrition, Health Technology, Other Health, Health, General Health, Consumer Electronics, Moses Austin, Benchmarking, Hormone, Exercise, Professor, Inflammation, Biomarker, Research, Sleep, Melatonin, University, Doctor of Philosophy, Life, Eye, Diet, Management, Publication, Skin, Cortisol, Ageing, Medical device

The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.

Key Points: 
  • The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.
  • Now, it provides users with unmatched real-time insights into their wellness, establishing a new benchmark for the continuous monitoring of these critical biomarkers.
  • Corti redefines health monitoring by offering continuous, real-time visibility into the body's key stress and sleep hormones, Cortisol and Melatonin, marking a first in the wearable market.
  • Moreover, we are actively working with partnering businesses to discover new applications, enhancing its integration into various health and wellness ecosystems.

EarliTec Diagnostics, Inc. Raises $21.5 Million in Series B Financing; Funds to Accelerate Commercialization of EarliPoint Evaluation and Further Product Development

Retrieved on: 
Tuesday, April 2, 2024
Neurology, Biometrics, Health, Mental Health, Medical Devices, Children, Health Technology, Consumer, Nexus, Diagnosis, Professor, Ageing, Child, Hope, CDC, Spectrum, Multimedia

The funds will be used to expand commercialization efforts and advance clinical research for the first-in-kind EarliPoint™ Evaluation (“EarliPoint”), which aids clinicians in the diagnosis and assessment of autism in children aged 16-to-30 months.

Key Points: 
  • The funds will be used to expand commercialization efforts and advance clinical research for the first-in-kind EarliPoint™ Evaluation (“EarliPoint”), which aids clinicians in the diagnosis and assessment of autism in children aged 16-to-30 months.
  • EarliPoint is the first personalized, quantifiable, and objective tool for children aged 16 months to 30 months suspected of having autism.
  • "EarliPoint represents a meaningful step forward in better, accessible care for autistic children.
  • "We are excited to partner with providers across the nation to deliver EarliPoint.

NTHU Launches Tsing Hua Talent Development Fund to Enhance Academic Excellence

Retrieved on: 
Tuesday, April 2, 2024
Fund Raising, Other Philanthropy, Philanthropy, University, Education, College, Research, Development, Technology management, NTHU, Professor, National Tsing Hua University, Publishing, Faculty, Research and development, Finance Secretary (India), Financial endowment, Multimedia, USD, Management

National Tsing Hua University (NTHU) in Taiwan launched the Tsing Hua Talent Development Fund to attract and retain exceptional faculty members.

Key Points: 
  • National Tsing Hua University (NTHU) in Taiwan launched the Tsing Hua Talent Development Fund to attract and retain exceptional faculty members.
  • View the full release here: https://www.businesswire.com/news/home/20240402305444/en/
    NTHU launched the Tsing Hua Talent Development Fund to attract and retain exceptional faculty members.
  • Setting up the Tsing Hua Talent Development Fund is a key strategy component.
  • Po-Wen Chiu, NTHU Vice President for Research and Development, explained that the Tsing Hua Talent Development Fund operates sustainably by utilizing donations, proceeds from industry-academia collaboration, and dividends from the fund.

Phison Collaborates with MediaTek to Propel Generative AI Computing and Services

Retrieved on: 
Tuesday, March 26, 2024
Software, Hardware, Data Management, Consumer Electronics, Technology, Artificial Intelligence, Semiconductor, Security, Engineering, Automotive Manufacturing, Aerospace, Manufacturing, AOI, UFS, ONFI, Synthetic media, GPU, MediaTek, Assistant, Professor, SSD, MIPI, GAISF, SDA, DRAM, NVM Express, Knowledge, Blog, Carbon footprint, MultiMediaCard, AI, IEEE-SA, PCI-SIG, Life, JEDEC, Nature, Electronics, Architecture, USB, IP, Ecosystem, UFSA, Solid-state drive, Leonardo da Vinci, Multimedia, Media, Automotive industry, Generative, Medical device

Under the collaboration, Phison's cutting-edge AI computing service, aiDAPTIV+ , will pair with MediaTek's premier generative AI service platform, MediaTek DaVinci, heralding a new epoch for AI computing and application services and accelerating the adoption of generative AI in everyday life.

Key Points: 
  • Under the collaboration, Phison's cutting-edge AI computing service, aiDAPTIV+ , will pair with MediaTek's premier generative AI service platform, MediaTek DaVinci, heralding a new epoch for AI computing and application services and accelerating the adoption of generative AI in everyday life.
  • (Graphic: Phison)
    MediaTek DaVinci is an advanced, open platform for generative AI services, built on the Generative AI Service Framework (GAISF).
  • Phison's aiDAPTIV+ features a pioneering SSD-integrated AI computing architecture that breaks down large AI models for concurrent operation with SSDs.
  • "aiDAPTIV+ is set to revolutionize AI model fine-tuning, and MediaTek DaVinci has already made significant strides in AI services,” said Dr. Wei Lin, CTO, Phison.

PreventScripts Names Two Sector Leaders to its Board of Directors

Retrieved on: 
Friday, March 15, 2024
Apps, Applications, Technology, Other Technology, Health Technology, Software, Networks, General Health, Pharmaceutical, Health, Data Management, Audit, Internal medicine, Risk management, Commonwealth Fund, Professor, Patient, University, MD, Texas Instruments, Semiconductor, National Technological University, National Association, Physician, Engineering, Silicon

As a seasoned business leader and strategic advisor, Jones brings experience in corporate governance, risk management and financial operations.

Key Points: 
  • As a seasoned business leader and strategic advisor, Jones brings experience in corporate governance, risk management and financial operations.
  • Jones serves on the advisory board of National Association of Corporate Directors – Nashville, where he also chairs the Program committee.
  • The clinical advisory board is comprised of physicians with a unique perspective and breadth of expertise to enhance PreventScripts’ comprehensive platform.
  • The board now includes:
    Dr. Rebecca Berman, MD, Professor and Internal Medicine Residency Program Director at the University of California, San Francisco